Clinical stage, histological subtypes and grade, residual tumor, the presence of ascites, performance status, and cancer antigen 125 (CA‐125) levels are all known prognostic factors in ovarian cancer.5 In addition to these established prognostic factors, interest has been growing in evaluating the systemic inflammatory and immune responses to cancer cells represented by the levels of neutrophils, lymphocytes, platelets, and acute‐phase proteins. This evidence concerns the gene MUC16 and ovarian cancer.